Dr. Jens Hillengass, MD, PhD
Claim this profileRoswell Park Cancer Institute
Expert in Multiple Myeloma
Expert in Plasma Cell Neoplasm
11 reported clinical trials
19 drugs studied
Area of expertise
1Multiple Myeloma
Global LeaderStage IV
HLA-A positive
CD28 positive
2Plasma Cell Neoplasm
Global LeaderStage IV
HLA-A positive
CD28 positive
Affiliated Hospitals
Clinical Trials Jens Hillengass, MD, PhD is currently running
Lifestyle and Supportive Care
for Multiple Myeloma
This clinical trial investigates the effect of non-chemotherapeutic interventions in patients with multiple myeloma or MDS. Non-chemotherapeutic interventions such as physical activity and nutritional interventions (e.g., modifications in diet) have been shown to positively affect the immune system and improve overall quality of life. Another purpose of this study is for researchers to learn how the addition of a beta-blocker (propranolol) to the standard treatment regimen in patients with newly diagnosed multiple myeloma affects immune response and quality of life. A study from the Mayo Clinic looked at multiple myeloma patients who were on a beta-blocker while undergoing chemotherapy and found that the use of a beta-blocker resulted in improved patient survival outcomes. Non-chemotherapeutic treatment options may help decrease symptoms and improve quality of life for patients with multiple myeloma.
Recruiting1 award N/A9 criteria
Belantamab Mafodotin + Lenalidomide
for Multiple Myeloma
This phase II trial investigates the effect of belantamab mafodotin and lenalidomide on minimal residual disease negative rates in patients with multiple myeloma with minimal residual disease positive after stem cell transplant. Belantamab mafodotin is a monoclonal antibody, called belantamab, linked to a chemotherapy drug, called mafodotin. Belantamab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as B-cell maturation antigen (BCMA) receptors, and delivers mafodotin to kill them. Lenalidomide may help block the formation of growths that may become cancer, and is used as a standard of care treatment for multiple myeloma. Giving belantamab mafodotin and lenalidomide may help to maintain minimal residual disease negativity in patients with multiple myeloma.
Recruiting1 award Phase 216 criteria
More about Jens Hillengass, MD, PhD
Clinical Trial Related2 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Jens Hillengass, MD, PhD has experience with
- Dexamethasone
- Lenalidomide
- Resistance Training
- SVN53-67/M57-KLH Peptide Vaccine
- Belantamab Mafodotin
- Abatacept
Breakdown of trials Jens Hillengass, MD, PhD has run
Multiple Myeloma
Plasma Cell Neoplasm
Bone Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jens Hillengass, MD, PhD specialize in?
Jens Hillengass, MD, PhD focuses on Multiple Myeloma and Plasma Cell Neoplasm. In particular, much of their work with Multiple Myeloma has involved Stage IV patients, or patients who are HLA-A positive.
Is Jens Hillengass, MD, PhD currently recruiting for clinical trials?
Yes, Jens Hillengass, MD, PhD is currently recruiting for 4 clinical trials in Buffalo New York. If you're interested in participating, you should apply.
Are there any treatments that Jens Hillengass, MD, PhD has studied deeply?
Yes, Jens Hillengass, MD, PhD has studied treatments such as Dexamethasone, Lenalidomide, Resistance Training.
What is the best way to schedule an appointment with Jens Hillengass, MD, PhD?
Apply for one of the trials that Jens Hillengass, MD, PhD is conducting.
What is the office address of Jens Hillengass, MD, PhD?
The office of Jens Hillengass, MD, PhD is located at: Roswell Park Cancer Institute, Buffalo, New York 14263 United States. This is the address for their practice at the Roswell Park Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.